587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
oleh: John Williams, Wilson Guzman, Minjie Zhang, Parker Johnson, Megan McLaughlin, Kurt Jenkins, Caitlin O’Toole, Magali Pederzoli-Ribeil, Margaret Karow, Ronan O’Hagan, Jennifer O’Neil, Ugur Eskiocak, Miso Park, Timothy Clackson
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.